{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Argentina Drug Manufacturers - General news", "home_page_url": "https://sharemaestro.com/newsreel/ar/healthcare/drug-manufacturers-general/", "feed_url": "https://sharemaestro.com/newsreel/ar/healthcare/drug-manufacturers-general/feed.json", "description": "Latest Drug Manufacturers - General company headlines from Argentina, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:46d7b26cc2205271fc5b52e3e603e999b45f4f7f77a85a476cec0cd874e86479", "url": "https://www.nasdaq.com/articles/dow-movers-amgn-honiv", "external_url": "https://www.nasdaq.com/articles/dow-movers-amgn-honiv", "title": "Dow Movers: AMGN, HONIV", "content_text": "In early trading on Friday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst performing Dow component thus far on the day is Amgen, trading down 1.4%. Amgen is showing a gain of 25.9% looking at the year to date performance. Two other components making moves today are Salesforce, trading down 1.4%, and Chevron, trading up 0.9% on the day. VIDEO: Dow Movers: AMGN, HONIV The views and opinions expressed herein are the views and opinio", "date_published": "2026-08-14T14:11:59+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "AMGN"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ed32847c-edb1-4325-a0b2-816cc1b01198/"}]}}, {"id": "source:4a3743dd6463ed105ffc9c1441902f440c6c025c3c9d0aedf7bd19fa086ad557", "url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "title": "Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is designed to integrate scientific capabilities with data and digital tools to support discovery and development of new medicines. This expansion adds another research hub to Amgen's global footprint and increases its geographic diversification in Asia. Amgen is not the only healthcare stock investing", "date_published": "2026-08-14T11:12:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AMGN"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ed32847c-edb1-4325-a0b2-816cc1b01198/"}]}}, {"id": "source:248772e86f849c54af48203e1ed82ca5c5a36ecd4687869763f578f9e29f78bd", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-win-233835472.html", "title": "Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?", "content_text": "On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. The clarification confirmed that in the United States, where overall survival was the sole primary endpoint, the trial failed to demonstrate a statistically significant improvement, missing it", "date_published": "2026-08-13T23:38:35+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ABBV"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0fa2d26a-d7df-4c40-9cd2-c6a6b72c7daa/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:0cf9b0bafc74581624313018706925e5b7ffbaa1f8371efffb9791a217b0b884", "url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-abbvie-inc-abbv-post-213306053.html", "title": "Could AbbVie Inc. (ABBV)\u2019s Post-Humira Transformation Drive the Next Phase of Growth?", "content_text": "AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations despite including a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Grounded in this solid operational momentum, ABBV raised its full-year 2026 adjusted diluted EPS guidance range to $14.08\u2013$14.28. Adding to its commercial trajectory, AbbVie's Allergan Aesthe", "date_published": "2026-08-13T21:33:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0fa2d26a-d7df-4c40-9cd2-c6a6b72c7daa/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Product Image (Photo: Bristol Myers Squibb)ZENBEXUS\u2122 (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb's targeted protein degradation platform PRINCETON, N.J., August 13, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has a", "date_published": "2026-08-13T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/0c837761-7fb9-4a5e-80fc-117704306a95/"}]}}, {"id": "source:06c9383a28c831d166e244315bed34ee2122d4e28940a6a805108264a483d25b", "url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/merck-mrk-stock-fair-value-200750935.html", "title": "Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck's pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the F", "date_published": "2026-08-13T20:07:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1dc1463c-a4c7-49b7-84d3-f203d8233829/"}]}}, {"id": "source:f3fab633d584d08932a2870ce562c4f22cbee989985bd7c4a16774be1769ba11", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-upgrades-biogen-abbvie-135201210.html", "title": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation", "content_text": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the company's late-stage pipeline offers significant upside that is not fully reflected in current valuations. The firm highlighted litifilimab and felzartamab as key assets, with clinical readouts expected over the coming year. Wolfe said litifilimab could become the first biologic approved for cut", "date_published": "2026-08-13T13:52:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "BIIB"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BIIB", "name": "Biogen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6e12059a-ee92-4d60-a6de-d22ba7fd457f/"}]}}, {"id": "source:91092dc042f21d2049015aebad19a6bc538732ca2d40d3ea2ae4bb9e13730615", "url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "external_url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "title": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results", "content_text": "MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Ob", "date_published": "2026-08-13T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "JNJ"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}]}}, {"id": "source:1fb430f4d1b71b75f67c6b22999fe9bcfcc63d54812fb79c7524b788dcf10acc", "url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "title": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?", "content_text": "Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat", "date_published": "2026-08-13T10:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:79ac6a4212879c1730f4d9d7d98c7f0bb6fab689172f414cdbb637101d7d0624", "url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "title": "Why Gilead Sciences (GILD) Is Back In The Spotlight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur", "date_published": "2026-08-13T09:11:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:5c3175630e88f5bc7762b7912b48c5c2bb9979bfb25b28db4bab7aa1d85378b1", "url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html", "external_url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html", "title": "Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...", "content_text": "This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration revenue from Pfizer and GSK being fully realized. R&D Expenses: $3.4 million in Q2 2026, down from $10.7 million in Q2 2025, due to reduced clinical activity following the early completion of the Utebzi Phase 3 trial. G&A Expenses: $6.5 million in Q2 2026, up from $5.9 million in Q2 2025, driven by higher business development", "date_published": "2026-08-13T05:01:24+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:cd43458cb731296f7072733bebb601944bde7b3165366430c94af54a3ae6c0ff", "url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "external_url": "https://finance.yahoo.com/healthcare/articles/valneva-reports-half-2026-financial-050000261.html", "title": "Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates", "content_text": "VALNEVA SE Total product sales of \u20ac64.0 million In-line with expectations; full-year guidance of \u20ac135 -150 million reaffirmed Solid cash position of \u20ac121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2 Pfizer remains optimistic about obtaining registration for the vaccine candidate3 Lyon (France), August 13, 2026 \u2013", "date_published": "2026-08-13T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:ca7bd9b0749ebb6a787227418d9a91b874566d623be8c3cd9e785328575d4a6f", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-pfizer-022900266.html", "title": "5 Insightful Analyst Questions From Pfizer\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to \"continued strategic progress\" and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management also pointed to the success of brands ", "date_published": "2026-08-13T02:29:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:f594c50a2829c0bc45dda3d205dd186eb2ff4b9d76ef9412fb23e929f303f7e5", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "external_url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "title": "5 Insightful Analyst Questions From Merck\u2019s Q2 Earnings Call", "content_text": "5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, \"Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.\" While market reaction was muted, management acknowledg", "date_published": "2026-08-12T23:41:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRK"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1dc1463c-a4c7-49b7-84d3-f203d8233829/"}]}}, {"id": "source:c9437f7c9df7d454cc88beb6f60a9bfcb966bbe769c2cf6e3f76f9b179b4936b", "url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/intuitive-surgical-isrg-beats-q2-211316667.html", "title": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return ", "date_published": "2026-08-12T21:13:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:5fcdf767edc608cff7fa5cd79c787c8ad280036dafb0cd1562c8c5a696de8af4", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "external_url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "title": "Sector Update: Healthcare Stocks Advance Late Afternoon", "content_text": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-12T19:58:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "MRK"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1dc1463c-a4c7-49b7-84d3-f203d8233829/"}]}}, {"id": "source:c8bfa06c7b9fbc27fe482807c5f11f2a9d5007b55d87a343f2383b67a9ff8c80", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "external_url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "content_text": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMY", "PFE", "MRK"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/0c837761-7fb9-4a5e-80fc-117704306a95/"}, {"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}, {"symbol": "MRK", "name": "Merck & Co., Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/1dc1463c-a4c7-49b7-84d3-f203d8233829/"}]}}, {"id": "source:91fbd6c7e56500b236257767bf61f9a38e6f84db47b9c0d6b62395e27b1fa08e", "url": "https://seekingalpha.com/news/4631770-tigo-energy-downgraded-at-roth-after-weak-revenue-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631770-tigo-energy-downgraded-at-roth-after-weak-revenue-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Tigo Energy downgraded at Roth after weak revenue guidance", "content_text": "[Aerial view of large electrical power plant with many rows of solar photovoltaic panels for producing clean ecological electric energy in morning. Renewable electricity with zero emission concept.] Bilanol/iStock via Getty Images Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO]) down 5.2% in Wednesday's trading as Roth Capital downgraded shares of the solar and energy storage firm to Neutral from Buy with a $1.30 price target, slashed from $7 previously, reflecting \"materially weaker growth visibility\" following its Q2 results. Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO])", "date_published": "2026-08-12T18:21:16+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:d9683bb69f74210c4baa0a6b901098dea0f33f985349c2426ac47e1792858586", "url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gilead-sciences-gild-expands-adc-181350587.html", "title": "Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead's oncology pipeline. Gilead is not the only company leaning into AI to reshap", "date_published": "2026-08-12T18:13:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:fef18f4e280685de7dbc6c50d1d93df3658df1ac06d7c1efcd63083fe71bf0e5", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "external_url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "date_published": "2026-08-12T17:29:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:9ea2ad3466fa89ef19f9ade7b95f627db7c366dc80cbdf58a5e5a3b73c6f014e", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-falls-while-172418737.html", "title": "Eli Lilly Stock Falls While Retatrutide Lawsuits Expand", "content_text": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for human use, sometimes hiding behind research use only labels. Lilly shares slipped roughly 0.8% Wednesday morning, but this fight is much bigger than one day's stock move. Lilly is defending a drug", "date_published": "2026-08-12T17:24:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:2100e637b2916ecb584e6b354b330a6f85d10b7b8fa369baf89de13620dc54c4", "url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/two-years-growth-barely-change-172001135.html", "title": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical", "content_text": "Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high and down about 15% over the past twelve months while the S&P 500 returned 22%. A fall that size usually leaves a stock cheap. This one still costs about 37.7 times its last twelve months of adjusted earnings, and what happens to that number by 2027 turns on a price the company has not set. Where The Multiple Actually Lands In 2027 Ana", "date_published": "2026-08-12T17:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:34e5fc56f789693bc2ea43ad70f9c5b8d91a45cd38f0be9635c5e8ee179ac038", "url": "https://finance.yahoo.com/healthcare/articles/absci-absi-early-abs-201-171116760.html", "external_url": "https://finance.yahoo.com/healthcare/articles/absci-absi-early-abs-201-171116760.html", "title": "Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci's recent early Phase 1 ABS-201 update and Eli Lilly's US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareh", "date_published": "2026-08-12T17:11:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:28f18b773ccaf69d248383eff739e70477d9fabb13d653ed5d20dbc99c06e7dd", "url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lilly-targets-black-market-retatrutide-165417136.html", "title": "Lilly Targets Black-Market Retatrutide Sellers", "content_text": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY fairly valued? Test your thesis with our free DCF calculator. The company filed six lawsuits against U.S. businesses it accuses of selling unapproved versions of the drug while it remains in clinical development. Retatrutide is still in Phase 3 trials for obesity, type 2 diabetes and related conditi", "date_published": "2026-08-12T16:54:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:dcf747a9ce3991456efb124defaa474880bc72c24deb26b5714a6ef69b7b8a84", "url": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/energy-pharma-giants-quietly-funding-161228567.html", "title": "The Energy and Pharma Giants Quietly Funding HDV\u2019s 3% Yield, and How Safe Each One Is", "content_text": "Quick Read XOM and JNJ earn 'Very Safe' dividend ratings inside HDV, backed by interest coverage of 56x and 64 consecutive annual raises. AbbVie's Skyrizi and Rinvoq are replacing Humira faster than expected, but Net Debt/EBITDA of 2.3x keeps a watchlist tag on its dividend. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout. Energy and pharma names account for the top four", "date_published": "2026-08-12T16:12:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "JNJ", "ABBV", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0fa2d26a-d7df-4c40-9cd2-c6a6b72c7daa/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:9073c5771f91b89c5e6ebe007a507f5ff605ec1bb6a0376e88f53fbdfcbb6eb0", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-advances-seltorexant-161141375.html", "title": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson's focus on higher growth therapeutic and medtech areas that are important for its lo", "date_published": "2026-08-12T16:11:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:de9e2e54cd03494c7c82bc314fdfb47b59256672fe30d3fa8a7dae8f56e46b3e", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "content_text": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "date_published": "2026-08-12T15:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:3bd1d4ad8bb7d0f063cdf91911b1e774e17c9b40b57c311e89283e66b3dc6fec", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "content_text": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20", "date_published": "2026-08-12T15:03:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "PFE", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:de3c374c70e34db2b4d2102009d09c2e0ca567a75389b9edbcb742024ff52e00", "url": "https://finance.yahoo.com/markets/stocks/articles/tngx-stock-dips-5-q2-144600756.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/tngx-stock-dips-5-q2-144600756.html", "title": "TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses", "content_text": "Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. Collaboration revenues were zero compared with $3.2 million a year earlier. Tango shares were down 4.8% on Tuesday, likely due to investor disappointment over the earnings miss. Higher operating expenses weighed on the result. TNGX's Q2 Results in Detail In the absence of a marketed product, Tango has no regular source of income. The company instead reports colla", "date_published": "2026-08-12T14:46:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:f8900e4219a35c506b5d42e453b4b58e174c0fd1ffeb50d0c1dc5612cece6fc9", "url": "https://www.nasdaq.com/articles/1-vanguard-etf-outperforms-sp-500-and-still-has-room-run", "external_url": "https://www.nasdaq.com/articles/1-vanguard-etf-outperforms-sp-500-and-still-has-room-run", "title": "1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run", "content_text": "Key Points The \"Magnificent Seven\" stocks account for over 53% of this Vanguard ETF. This has helped the ETF outperform the S&P 500 in 13 of the past 20 years. Sluggish performance among its top 10 holdings has slowed returns this year.10 stocks we like better than Vanguard Morningstar Growth ETF \u203a The S&P 500 is the stock market's most important index, tracking the 500 largest American companies on the market. It has become the main benchmark investors use to measure their returns, with outperformance and underperformance largely dependent on how it compares. Although investing in an S&P 500 ", "date_published": "2026-08-12T14:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Analyst action", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:86d62dd42602561cf8e8cd009a104631483eef215b056b5717b74345e252d30d", "url": "https://finance.yahoo.com/m/fccbac36-96b9-3db5-b544-3fb53ab9e0c5/ibd-50-stocks-to-watch%3A.html", "external_url": "https://finance.yahoo.com/m/fccbac36-96b9-3db5-b544-3fb53ab9e0c5/ibd-50-stocks-to-watch%3A.html", "title": "IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point", "content_text": "Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading", "date_published": "2026-08-12T14:29:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:46b3f23a3cbbf72aa4fa4eff600d629dac6ffd5d600b532526e1abeb25fd4333", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "U.K. regulator reaffirms safety of childhood vaccination", "content_text": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "date_published": "2026-08-12T13:13:40+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Market update", "AZN", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/6ac17112-224a-4034-ba52-6d46ce64f660/"}, {"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:51d09f49a249edf74240a838044ca42e1d3db275594bc2a3bd21270e54e907de", "url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "external_url": "https://finance.yahoo.com/healthcare/articles/intuitive-surgical-oppenheimer-now-bullish-125931309.html", "title": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\"", "content_text": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart. Analyst Suraj Kalia said the change reflects \"a more nuanced risk-reward assessment at these levels.\" On the positive side, the firm views U.S. competition as a \"non-factor,\" with field checks suggesting \"some unique workflow challenges for Ottava that limit long-term appeal\" and real-estate issues for Hugo. It added that Intuitive's customized price-volume contracts complicate c", "date_published": "2026-08-12T12:59:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:fe4e389d770d2e29836a7265fb0b54c990f811b726528a98df8a2831a7b0d9f0", "url": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "title": "Why Revolution Medicines May Be Big Pharma\u2019s Next Takeover Target", "content_text": "Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform ", "date_published": "2026-08-12T12:50:24+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "JNJ", "PFE", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:93a8437a003e42bdc1cec61e325e382b08164d5e79e56bcc2ecbd8cc4c72cb21", "url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/oppenheimer-sees-500-intuitive-surgical-122519688.html", "title": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall", "content_text": "This article first appeared on GuruFocus. Intuitive Surgical (NASDAQ:ISRG) rose 0.90% premarket after Oppenheimer upgraded the robotic surgery company to Outperform from Perform with a $500 price target. The firm's case rests less on Intuitive than on its competitors: workflow integration problems for Johnson & Johnson's (NYSE:JNJ) Ottava system and physical footprint constraints for Medtronic's (NYSE:MDT) Hugo, potentially leaving the da Vinci franchise without a credible domestic challenger in the near term. Oppenheimer also pointed to the Per Click Model as a way into lower-acuity ambulator", "date_published": "2026-08-12T12:25:19+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:8f00dd77c6a30ec1c336d4841cd0b710cdd43341970cfce3d9c8039415502e54", "url": "https://finance.yahoo.com/markets/stocks/articles/p-500-yield-lowest-history-121515789.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/p-500-yield-lowest-history-121515789.html", "title": "The S&P 500 Yield Is the Lowest in History: 5 Members of the Legacy Index Yield 6% or More", "content_text": "Quick Read The S&P 500's combined dividend yield hit a record-low 1.04%, but five index members still deliver dividends of 6% or more, all rated Buy. General Mills (GIS) yields 6.9% at just 10x 2026 earnings, while Verizon (VZ) has raised its dividend for 20 consecutive years. Since 1926, dividends have contributed 32% of the S&P 500's total return, and payers have delivered more than double the returns of non-payers. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor", "date_published": "2026-08-12T12:15:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:7f86b5227bc22a9752a278a909c94b778e142bfa5917ec7e264a507df28aa63b", "url": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "external_url": "https://finance.yahoo.com/healthcare/articles/madrigal-appoints-john-c-reed-120000934.html", "title": "Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors", "content_text": "Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (\"J&J\") and is a member of J&J's Executive Committee, where he leads research and development across oncology, immunology, neuroscie", "date_published": "2026-08-12T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "JNJ", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:a98bf40dc28964028c314674c98bb3ba67f672de930dcedcae5839f480c10811", "url": "https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html", "external_url": "https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html", "title": "InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001", "content_text": "IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company SEATTLE & CAMBRIDGE, Mass., August 12, 2026--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane pro", "date_published": "2026-08-12T11:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:42172907b7c3be71dbc848985f4a5239d8f2f8916ed25fc4e50f87f9eb8e2147", "url": "https://finance.yahoo.com/healthcare/articles/arbutus-reports-second-quarter-2026-113000778.html", "external_url": "https://finance.yahoo.com/healthcare/articles/arbutus-reports-second-quarter-2026-113000778.html", "title": "Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update", "content_text": "Arbutus Biopharma Corporation Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus shareholders Filed three international patent enforcement lawsuits against Pfizer and BioNTech related to lipid nanoparticle (LNP) technology Achieved alignment with the U.S. Food and Drug Administration (FDA) on a proposed imdusiran Phase 2b clinical trial design WARMINSTER, Pa., Aug. 12, 2026 (GLOB", "date_published": "2026-08-12T11:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:bf7defe4a71158af0a1bd84bf51ac804a6c1a409a21dd1ca573562c764d9813c", "url": "https://seekingalpha.com/news/4631300-lilly-files-six-lawsuits-to-crack-down-on-black-market-retatrutide-weight-loss-shots?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4631300-lilly-files-six-lawsuits-to-crack-down-on-black-market-retatrutide-weight-loss-shots?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots", "content_text": "[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide remains an investigational Phase 3 molecule, and no retatrutide medicine has been approved for human use by any regulator worldwide. The FDA has made c", "date_published": "2026-08-12T09:41:38+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:598e9075e70015a8ed86ba0f87e4ec63ce23413315cab77717ad26d7d1f31fd6", "url": "https://finance.yahoo.com/healthcare/articles/lilly-calls-online-platforms-payment-093000432.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lilly-calls-online-platforms-payment-093000432.html", "title": "Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market", "content_text": "Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business\u2014social media and e-commerce platforms, credit card companies, payment processors an", "date_published": "2026-08-12T09:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:ee2012b426ba5b32f8f9770cbf19ac68a207ef1594a8b2065c3c2e011868767c", "url": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "external_url": "https://www.nasdaq.com/articles/if-i-were-my-40s-id-buy-vanguard-etf-warren-buffett-recommended-and-hold-it-forever", "title": "If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever", "content_text": "Key Points Warren Buffett steered the Berkshire Hathaway holding company to market-crushing returns for 60 years. He often said everyday investors could do well by simply buying an exchange-traded fund that tracks a diversified index like the S&P 500. In February 2014, he specifically recommended the Vanguard S&P 500 ETF because of its ultra-low fees, and it could help investors achieve a secure retirement. 10 stocks we like better than Vanguard S&P 500 ETF \u203a Warren Buffett served as chief executive officer of the Berkshire Hathaway(NYSE: BRKA)(NYSE: BRKB) holding company between 1965 and 2025", "date_published": "2026-08-12T09:17:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "JNJ", "LLY", "DJNJ3"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/3293f367-96cf-4628-a848-a3246a3ac30f/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}, {"symbol": "DJNJ3", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/b5562b07-7c28-40d3-9eca-d661ba65693a/"}]}}, {"id": "source:f755a236060581c0463b2dfb458c610a2dbef387eea1d6ce6f9c007c37d67f2d", "url": "https://finance.yahoo.com/healthcare/articles/amgen-open-science-innovation-center-082500598.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amgen-open-science-innovation-center-082500598.html", "title": "AMGEN TO OPEN NEW SCIENCE & INNOVATION CENTER IN GENOME VALLEY, HYDERABAD", "content_text": "New Site Will Support Global Research and Development Capabilities and Advance Scientific Research HYDERABAD, India, Aug. 12, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to open a new Science and Innovation Center at Genome Valley in Hyderabad. The center will join Amgen's global Research and Development network, which consists of seven research laboratories, further expanding the company's research and scientific capabilities.L to R: Nikhil Charavarthi, Commissioner, Industries; Sarvesh Singh, CEO, Telangana Life Sciences; Krishna Aditya, Special Secretary, Industries; Shr", "date_published": "2026-08-12T08:25:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AMGN"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ed32847c-edb1-4325-a0b2-816cc1b01198/"}]}}, {"id": "source:a596ccab877ec2f06c50e3078954b688b7d923aa1ab60cec82377ed09c236908", "url": "https://finance.yahoo.com/healthcare/articles/absci-absi-11-0-lilly-071042096.html", "external_url": "https://finance.yahoo.com/healthcare/articles/absci-absi-11-0-lilly-071042096.html", "title": "Absci (ABSI) Is Up 11.0% After Lilly Backs ABS-201 With US$40 Million Investment \u2013 Has The Bull Case Changed?", "content_text": "Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we'll examine how Eli Lilly's US$40 million investment and advisory role could reshape Absci's investment narrative around ABS-201. ", "date_published": "2026-08-12T07:10:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/5da68e1c-2b20-423f-ad1f-96e403154df2/"}]}}, {"id": "source:d936ea597992f68883228c46de03f25cf4cbf918eeb62deae0bbb32d6f964680", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-agreed-44-million-053939481.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-pfe-agreed-44-million-053939481.html", "title": "Pfizer (PFE) Agreed To A $44 Million Chantix Settlement", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. The company reported positive topline Phase 3 results for LITFULO in adults and adolescents with nonsegmental vitiligo, highlighting progress in its immunology pipeline. Both developments arrive as investors track Pfizer's legal exposures alongside late stage trial data that could inform future portfolio and r", "date_published": "2026-08-12T05:39:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/eb142b0f-7f11-4070-8810-ce3d083de9e4/"}]}}, {"id": "source:dca284bb066b60bbf91f93101142188fab3d49b0b2476f9732ab4e090f4f98c0", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "external_url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-400bn-deal-unravelled-040028643.html", "title": "How AstraZeneca\u2019s $400bn deal unravelled", "content_text": "One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly \u00a34.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T04:00:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "AZN"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/6ac17112-224a-4034-ba52-6d46ce64f660/"}]}}, {"id": "source:dc2ea09e3fe6360e068c698276bfac729fd82e6bbe5bfb2d096dbc2191977eaf", "url": "https://finance.yahoo.com/healthcare/articles/3-healthcare-stocks-open-questions-025322220.html", "external_url": "https://finance.yahoo.com/healthcare/articles/3-healthcare-stocks-open-questions-025322220.html", "title": "3 Healthcare Stocks with Open Questions", "content_text": "3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points. Regardless of these results, investors must exercise caution as many businesses in this space are subject to heavy regulation that can influence their earnings potential. With that said, here are three healthcare stocks we're steering clear of.", "date_published": "2026-08-12T02:53:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "Argentina", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/3a5d33fd-be4c-422b-935c-a03cd6ca6008/"}]}}, {"id": "source:b6c903c7fb892eeaa0393e75b65ce4f7d53a7f88f20709d57a8ef10af666d051", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-wins-canada-reimbursement-221514425.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbvie-abbv-wins-canada-reimbursement-221514425.html", "title": "AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks.NYSE:ABBV E", "date_published": "2026-08-11T22:15:14+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "Argentina", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/0fa2d26a-d7df-4c40-9cd2-c6a6b72c7daa/"}]}}]}